June 11, 2021
By Alec Doherty
Oncology has largely been immune to the reimbursement pressures that challenge virtually every other drug category. But that’s changing, and fast, noted RE’s Chairman Roger Longman in a speech at the recent Sachs Oncology Innovation Forum. Oncology is beginning to face new pricing hurdles – from biosimilars, from discount-focused competitors, and even from pharma analysts at major investment banks! You can view Roger’s presentation here.
